' '
Deutsch | English    

Research Database PMU-SQQUID

Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options.
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Trinka, E; Kraus, J;
Drug Discov Today. 2011; 16(1-2):8-21


Harrer Andrea
Kraus Jörg
Oppermann Katrin
Pilz Georg
Trinka Eugen
Wipfler Peter


Multiple sclerosis (MS) is the most common chronic neurological disease in young adults in the western world. There was no specific treatment available for this serious disorder until the introduction of the immunomodulatory drug interferon-β in the mid-1990s. Since then, the number of agents and treatment strategies for MS has increased rapidly. Deeper knowledge on the heterogeneous nature of MS cleared the way for several more specific, more effective and more comfortable therapies. Here, because of the exciting recent developments concerning oral treatment forms for MS, we summarize the current state of approved and future therapy options. In particular, we highlight oral treatment options in MS.

Useful keywords (using NLM MeSH Indexing)

Administration, Oral


Drug Approval

Drug Design



Multiple Sclerosis/drug therapy

Multiple Sclerosis/therapy*